We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Calculus Vct Plc | LSE:CLC | London | Ordinary Share | GB00BYQPF348 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 51.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 42.00 | 60.00 | 51.00 | 51.00 | 51.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 491k | -535k | -0.0076 | -67.11 | 36.14M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 51.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/12/2024 | 16:24 | UK RNS | Calculus VCT PLC Issue of Equity - 18 December 2024 |
| 05/12/2024 | 19:52 | ALNC |  EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations |
| 05/12/2024 | 17:25 | UK RNS | Calculus VCT PLC Half-year Report |
| 14/10/2024 | 12:40 | UK RNS | Calculus VCT PLC Publication of a Prospectus |
| 08/10/2024 | 16:23 | UK RNS | Calculus VCT PLC Transaction in Own Shares |
| 09/9/2024 | 21:02 | ALNC | TRADING UPDATES: Live Co fails to reach agreement with creditor |
| 09/9/2024 | 10:48 | UK RNS | Calculus VCT PLC Statement re Intention to Fund Raise |
| 29/8/2024 | 16:32 | UK RNS | Calculus VCT PLC Issue of Equity |
| 22/8/2024 | 15:27 | UK RNS | Calculus VCT PLC Results of Annual General Meeting |
| 31/7/2024 | 16:44 | UK RNS | Calculus VCT PLC Issue of Equity |
Calculus Vct (CLC) Share Charts1 Year Calculus Vct Chart |
|
1 Month Calculus Vct Chart |
Intraday Calculus Vct Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/10/2017 | 13:54 | Clinical Computing - Software solutions for the Renal Dialysis Market | 46 |
| 29/6/2007 | 13:21 | Clinical Computing up 27% | 270 |
| 07/7/2006 | 12:09 | Clinical computing - countdown to lift-off (6 August 2003) | 9 |
| 14/6/2006 | 07:33 | CLC with Charts & News | 12 |
| 09/3/2000 | 22:08 | Clinical Computing - recovering rapidly | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 30/12/2024 08:20 by Calculus Vct Daily Update Calculus Vct Plc is listed in the Investment Advice sector of the London Stock Exchange with ticker CLC. The last closing price for Calculus Vct was 51p.Calculus Vct currently has 70,857,048 shares in issue. The market capitalisation of Calculus Vct is £36,137,094. Calculus Vct has a price to earnings ratio (PE ratio) of -67.11. This morning CLC shares opened at 51p |
Posted at 12/10/2010 06:33 by 22hoper The Hydra Management part of the company is generating good cash and with new contracts things are looking up for clc. |
Posted at 30/10/2007 16:19 by orange1 powwowWorrying about why a share you don't own has gone from 50p to 3p... happy days. I have held from 170p and am definitely "at odds" as to why it went from 170 to 3p. Luckily I have never held any other share so it has been enabled me to concentrate on this one. LOL! |
Posted at 09/10/2007 10:12 by lionelh I've been in this share for five or six years now since I saw a buy recommendation in Techinvest. In that time it has lost over 90% of its value (I can remember when it was nearly 50p per share). My exposure to it has been small so I held on. For the first time I am seriously considering topping-up and averaging down. Continued improving newsflow can only start to move the share price ahead for a revaluation soon. It appears to be sticking a bit like ULT where continuing positive newsflow, including large NHS interest, over a period of time has failed to be recognised by the market. Cancellation of official listing should be a large saving but may lose instittional investors. I presume it will be an AIM listing instead. Good luck all patient investors. |
Posted at 12/9/2007 09:05 by readbetweenthelines I would suggest getting in on the ground level here and holding this for the coming year with the new contracts due : "It said it looks forward to reporting continued progress in the year ahead as nine clinical vision implementations will go live in 2007 "LONDON (Thomson Financial) - Clinical Computing PLC said full-year pretax loss narrowed by 39.6 pct and revenues increased by 7.6 pct, attributable to the restructuring programme initiated in the second half of 2005, adding it looksforward to improved results in the year ahead. The company, which develops computer systems for the healthcare sector, posted pretax loss of 964,638 stg from last year's 1.54 mln stg, while revenues stood at 1.78 mln stg against 1.65 mln stg. It said it looks forward to reporting continued progress in the year ahead as nine clinical vision implementations will go live in 2007. It said its restructuring programme is well underway with a new office opened in Ipswich, providing a base to concentrate on expanding product portfolio and delivering against the product roadmap. Reasons to buy at current level We`re priced at dilution levels , the chairman holds over 10% at double the level of todays stock price .Over 50% held tightly by directors and the recent RNS:29/06/2007 LONDON (Thomson Financial) - Clinical Computing PLC said it expects growth in revenue for the first half compared with the same period last year despite a weak US dollar, adding that it remains confident about its prospects. At its AGM, the developer of computer systems for the healthcare sector said it has seen its US and Australian operations generating cash during the first half. The group added that it is now working to implement its eight active Clinical Vision flagship products, with a future revenue opportunity above 1 mln stg. All of this and only a £1 million market cap , the market makers have priced this one incorrect . Buy |
Posted at 01/7/2007 10:28 by rolfe and nolan I expect to see CLC trading in double figures this coming week. CLC will now bear the fruit of it's labours. |
Posted at 29/6/2007 12:01 by orange1 Well, I never ....We've only gone out and won ourselves another contract! Let the mad buying frenzy begin. Today's AGM Statement in full: "Since the Company began its restructuring plan in the first half of 2005 the Group has reported steady progress with its operations and improving financial performance with losses decreasing steadily over each of the subsequent reporting periods. The following trading areas were noted by Howard Kitchner, Chairman: * The Company is expecting to report comparative period on period improvements to top line revenues for the six month period to 30 June 2007. This is in spite of the significant weakening of the US dollar, over the comparative periods. * During the first half of 2007 the Company has seen its US and Australian operations generating cash. At the present time the Company continues to fund its UK operations with debt. * Since the announcement of our 2006 final results on 27 April 2007, the Group has won a contract in the US to support the renal service department of a hospital with CLINIICAL VISION. Additionally, two customers have completed the implementation of CLINCIAL VISION. * The Group is now working through eight active CLINICAL VISION implementations, with a future revenue opportunity of over #1,000,000. * With respect to the UK market, the Company continues to build partnerships and work with our UK customer base on an upgrade programme from PROTON to CLINICAL VISION. With these trading conditions in mind the Board remains confident about the Group's prospects and continues to view the future with optimism." P.S. What good typists they have over at CLC: is the flagship product called CLINIICAL VISION or CLINCIAL VISION? |
Posted at 22/6/2007 15:46 by bracke "Any reason for such a low NMS?"To stop selling of a large number at the bid price without a requote? |
Posted at 22/6/2007 14:15 by cyberpost so this is the share you were secretly emailing 'knowing' about ? |
Posted at 29/11/2006 13:18 by orange1 The chairman of CLC has been a big buyer of the shares of late together with a "connected person" substantial shareholder David Altschuler. The chairman Howard Kitchner is a Chartered Accountant who has worked in merchant banking, investment banking and the leasing industry. He is currently chairman of National Leasing & Finance Co. David Altschuler is also a chartered accountant and also at National Leasing & Finance Co. Back in the early 90s the two of them had a brief career as film producers (Leon the Pig Farmer with walk on parts to boot). If I were one of ADVFN's more notorious rampers I would be suggesting that this can only mean one thing: that United Pictures or Time Warner (pick your film producer of choice) are about to reverse into CLC and that now is the time to fill your boots before the rest of the world catches on. LOL! |
Posted at 23/3/2006 10:16 by orange1 BakuninWelcome! I can't quite believe that somebody is actually interested in this minnow. The £1.25m annual revenue in maintenance fees which I have previously mentioned is based on the figure in the notes to the most recent annual accounts £1.1m uplifted so as to reflect the new contracts. CLC have a large stable customer base who pay maintenance fees every year. Not all of these were originally sold CLC products. A chunk of these customers were acquired in the 90s when CLC acquired them from Fresenius (from memory). I agree that it is unlikely that these are paying 17.5% of the licence fee. It is probably a much lower percentage. But for those acquiring CV4 a rate of 15 to 17.5% is not unreasonable I believe. The CV4 licence fees are higher than 50k but, as you say, there have not been many. It has always been the case with CLC that a spate of licences sold would transform the fortunes of the company. Just £1m to £2m of licences sold in one year woulld have done the trick. But sadly this has never come to pass. Based on the figures last September, the company's financial situation and prospects did not seem to warrant the rock bottom rating we have today. But there has been no news since then and the price today tells its own sad story. I still hold but much more in hope than expectation. The upcoming results should tell us more. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
